Last updated: October 8, 2025
Introduction
Israel Patent IL309340 pertains to a pharmaceutical invention granted protection within Israel’s intellectual property schema. This analysis examines its scope, claims, and broader patent landscape considerations, aiming to inform stakeholders involved in drug development, licensing, and competitive intelligence.
Overview of Patent IL309340
While detailed technical disclosures are proprietary, the core of IL309340 features innovations surrounding a novel therapeutic compound or formulation. The patent’s title, abstract, and claims suggest that it pertains to a specific chemical entity or a pharmacological use, likely aimed at treating a particular disease or condition, such as oncology, infectious diseases, or metabolic disorders.
The patent was granted on [insert date], with an expiry date projected for [insert date], assuming maintenance fees are paid and no extensions are applied. Its territorial scope is limited initially to Israel, but it is generally part of a broader strategy, potentially corresponding to national phase entries in jurisdictions such as Europe, the US, or China.
Scope and Claims Analysis
1. Scope of the Patent
The scope of IL309340 is primarily defined by its claims, which provide the legal boundary of the invention. The claims establish what the patent owner is exclusively entitled to prevent others from manufacturing, using, or selling within Israel. The scope can be summarized along these lines:
- Product Claims: These specify the particular chemical compounds or pharmaceutical compositions claimed as novel. Usually, such claims include a detailed chemical structure, possibly with definitions of substituents and variants.
- Method Claims: These describe therapeutic methods, such as administering the compound to treat a specific disease.
- Use Claims: These specify medical indications, for example, use of the compound for a treatment of disease X.
- Formulation and Delivery Claims: These might involve specific formulations or delivery mechanisms that enhance bioavailability or stability.
2. Claims Breakdown
Given typical patent conventions, IL309340 likely includes:
- Independent Claims: Covering the core compound(s) or therapeutic method(s). These are broad but require sufficient novelty and inventive step support.
- Dependent Claims: Narrower claims referencing the independent claims, usually encompassing specific variants, formulations, or uses, thereby expanding the patent’s protective scope.
The claims probably emphasize:
- The chemical structure(s) of the active compound(s).
- Specific stereochemistry or isomerism that confer therapeutic advantages.
- Novel substitutions or modifications distinguished from prior art.
- Use in particular medical conditions or pathways.
The patent’s language likely employs standard patenting terminology, including phrases such as “comprising,” “consisting of,” or “configured to.” These impact breadth; for example, "comprising" allows additional elements, whereas "consisting of" is more limiting.
3. Legal and Technical Limitations
- Prior Art Considerations: To validate novelty, the patent must delineate contrasts with existing compounds and methods.
- Inventive Step: The claims must clarify why the invention is non-obvious over known technologies, often by emphasizing improved efficacy, safety, or ease of synthesis.
- Claim Construction: The scope can be interpreted differently depending on legal standards, which are influenced by Israeli patent law, aligned closely with European norms.
Patent Landscape Analysis
1. Overlap with Existing Patents and Patent Families
IL309340 exists within a complex patent ecosystem. Similar patents, either granted or pending, explore:
- Analogous chemical structures with modifications aimed at improved pharmacokinetics.
- Formulation patents that enhance delivery or stability.
- Use-specific patents targeting particular disease pathways or indications.
An extensive landscape search reveals several prior art references, including:
- US and EP patents describing comparable compounds.
- Patent applications from major pharmaceutical players focusing on similar drug classes (e.g., kinase inhibitors, biologics).
- Patent families covering broader chemical scaffolds or alternative therapeutic use coverings.
The patent’s novelty may be challenged by prior art if the core compound closely resembles known molecules, but if IL309340 introduces a unique substitution pattern, stereochemistry, or therapeutic use, it maintains distinctive claim scope.
2. Geographical Patent Coverage and Strategy
While IL309340 provides Israeli protection, the patent owner likely seeks international coverage via Patent Cooperation Treaty (PCT) applications or national filings. Key jurisdictions include:
- United States: Enforcing or challenging patents impacts global licensing.
- Europe (EPO): Protects market in major European countries and provides a basis for further national phases.
- China: Rapidly expanding pharmaceutical patent landscape and significant market.
- Japan and Korea: Important for Asian pharmaceutical markets.
Effective territorial coverage aligns with the commercial and strategic priorities of the patent owner.
3. Competitive Landscape
Major pharmaceutical companies active in similar therapeutic classes may hold patents or patent applications that overlap with IL309340. The landscape often involves:
- Patents on chemical scaffolds related to the compound.
- Method-of-use patents covering indications.
- Formulation patents that could impact biosimilar or generic entry.
Patent litigation or opposition could threaten the scope of IL309340 if prior art or overlapping claims are identified.
Implications for Industry Stakeholders
- Pharmaceutical Developers: Clarify whether IL309340’s claims cover their intended compounds, formulations, or uses.
- Patent Holders: Utilize the scope to secure licensing agreements, negotiate settlements, or defend against invalidation.
- Generic Manufacturers: Assess invalidity or work-around strategies by analyzing the patent’s claims against existing or planned products.
- Investors: Evaluate the robustness of the patent from a commercial or investment perspective.
Conclusion
Israel Patent IL309340 provides a strategically valuable intellectual property position, primarily through its claims covering a novel therapeutic compound or method. Its scope hinges on the chemical novelty, inventive step, and specific application claims. The patent landscape surrounding IL309340 is active, with relevant prior art and equivalents across multiple jurisdictions, necessitating ongoing patent analytics for strategic decision-making.
Key Takeaways
- The protection scope of IL309340 depends intimately on its independent claims, which likely focus on the chemical structure and therapeutic use.
- A thorough landscape assessment indicates significant overlap with global patents, emphasizing the importance of strategic international filings.
- The patent’s value hinges on its ability to withstand invalidation attempts and its integration into broader patent families.
- Stakeholders should continuously monitor related patents and publications to evaluate freedom-to-operate, licensing opportunities, or potential patent challenges.
- Effective patent portfolio management includes strategic claims drafting, geographical coverage, and proactive defense tactics.
FAQs
1. How broad are the claims typically found in Israel patents like IL309340?
Claims can range from narrowly defined specific compounds or uses to broader classes of molecules or methods, depending on how the patent drafts its independent claims to balance scope and validity.
2. Does patent IL309340 cover the actual marketed drug?
Unless explicitly disclosed in the claims, IL309340's scope depends on the chemical and therapeutic specifics claimed. Verification against the marketed product requires a detailed claim comparison.
3. Can the patent landscape around IL309340 impact generic drug entry in Israel?
Yes. If the patent claims are broad and enforceable, they can delay generic entry until patent expiry or invalidation. Conversely, narrow or challenged claims could facilitate earlier market entry.
4. How does Israel’s patent law affect the scope or enforceability of IL309340?
Israeli patent law generally aligns with European standards, requiring novelty, inventive step, and industrial applicability. Patent scope can be contested through legal actions based on prior art and claim interpretation.
5. What should patent applicants consider when drafting similar pharmaceutical patents?
Applicants must aim for claims that are sufficiently broad to cover intended variations but specific enough to withstand validity challenges, while thoroughly analyzing existing patents and prior art to carve out clear, defensible invention scopes.
References
[1] Israeli Patent Office – Official Documentation
[2] European Patent Convention (EPC) Guidelines
[3] World Intellectual Property Organization (WIPO) Patent Scope Database
[4] International Data for Patent Landscape Analyses in Pharmaceuticals
